Member access

4-Traders Homepage  >  Shares  >  Nyse MKT  >  Navidea Biopharmaceuticals Inc    NAVB   US63937X1037

News SummaryMost relevantAll newsSector news 

Navidea Biopharmaceuticals Inc : StockCall Pre-Market Review on Hologic, St. Jude Medical, ResMed, and Navidea Biopharma

03/15/2013 | 07:05am US/Eastern

LONDON, March 15, 2013 /PRNewswire/ --

Markets continued their ascent as The Dow Jones closed high for the tenth consecutive day. Major indices including S&P and NASDAQ also ended the session in the green zone. While a report alluded to the 'flare up' in housing foreclosures, strong job data provided positive fillip to the markets. However, with the sharp rise in the market, skepticism is also taking hold as a leading financial expert Kerry Balenthiran warned that the markets may turn bearish this year. Our research team took a look at Healthcare sector, more specifically the Medical Appliances & Equipment industry which includes major companies like Hologic Inc. (NASDAQ: HOLX), St. Jude Medical Inc. (NYSE: STJ), ResMed Inc. (NYSE: RMD) and Navidea Biopharmaceuticals Inc. (NYSE: NAVB). StockCall analysts initiated preliminary technical research on HOLX, STJ, RMD, and NAVB. These free reports are accessible by signing today at

Hologic Inc. extended its 52 weeks gain by closing 0.99 percent higher. The stock ended its Thursday session at $22.46, while its highest price point for yesterday's session stood at $22.47. It traded 1.18 million shares, down from its average daily volume high of 2.80 million. The medical equipment maker traded in the range of $16.18 and $23.96 in the past 52 weeks and currently it is trading near its high price point. The company commands market capitalization of $6.01 billion and it reported its latest EPS at -$0.35. Hologic Inc. stock gained more than 6 percent in the past 52 weeks. The free technical analysis on HOLX is available by signing up at

St. Jude Medical Inc. slipped marginally with lower volume to end its latest session at $42.90. The stock ended 0.21 percent lower than its previous close. Its volume for the day stood at 2.15 million shares. The stock is currently trading higher than its 20-day SMA of $42.89 but lower than its 50-day SMA of $42.91, showing a neutral trend. Its first resistance level is at $43.05 while it may tumble to $42.65 before receiving any support. St. Jude Medical's stock is up 20.95 percent on a YTD basis, while offering 2.14 percent dividend yield. Register now to download the free research on STJ at

ResMed Inc. ended yesterday's trading session at $43.74, up 0.81 percent from its previous close. With its latest upward move, the stock is now up 6.92 percent on a YTD basis, while its 52 weeks gain stands at 45.9 percent. The company oscillated in the range of $43.27 and $43.81 during Thursday's session. It traded 958, 085 shares and showed a mild bullish trend. The stock may touch $43.95 in the coming sessions. Upon breaching this level, its next resistance level is at $44.25. Free report on RMD can be accessed by registering at

Navidea Biopharmaceuticals Inc. sank in Thursday's session. The stock closed 7.91 lower at $2.91 with above average volume of 4.08 million shares, showing a bearish trend. The company has its first support level at $2.75. Upon breaching this level, its next support level is at $2.56. Navidea Biopharma is currently trading near its 52 weeks low of $2.14, while its 52 weeks high stands at $4.77. The company commands market capitalization of 312.51 million. The company is also trading below its short-term and long-term average price, further confirming a bearish trend. Register with StockCall and download the research on NAVB for free at

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at


React to this article
02/27 NAVIDEA BIOPHARMACEUTICALS : Macrophage Therapeutics, a Subsidiary of Navidea Bi..
02/26 NAVIDEA BIOPHARMACEUTICALS : to Announce Fourth Quarter and Year-End 2014 Financ..
02/25 NAVIDEA BIOPHARMACEUTICALS : Lymphoseek® Results from Phase 3 Clinical Trial in ..
02/18 NAVIDEA BIOPHARMACEUTICALS : Lymphoseek® Data Presented in European Medical Conf..
02/17 NAVIDEA BIOPHARMACEUTICALS : Lymphoseek® Results from Phase 3 Clinical Trial in ..
02/11 NAVIDEA BIOPHARMACEUTICALS : to Report Preliminary 2014 Revenue and Present at B..
02/09 NAVIDEA BIOPHARMACEUTICALS : Change in Directors or Principal Officers, Other Ev..
02/09 NAVIDEA BIOPHARMACEUTICALS : Reports Preliminary 2014 Revenue; Provides Update o..
02/02 NAVIDEA BIOPHARMACEUTICALS : to Report Preliminary 2014 Revenue and Present at B..
01/29 NAVIDEA BIOPHARMACEUTICALS : Lymphoseek® Performance vs. Sulfur Colloid in Breas..
Dynamic quotes